The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: A demonstrator study using the IL-1 receptor antagonist anakinra

Journal of Immunotoxicology

Volumn 10, Issue 1, 2013, Pages 96-105

  Van Mierlo, Geertje J D ^a   Cnubben, Nicole H P ^a   Kuper, C Frieke ^a   Wolthoorn, Jasja ^a   Van Meeteren Kreikamp, Angelique P ^a   Nagtegaal, MacHiel M ^a   Doornbos, Robert ^a,b   Ganderup, Niels Christian ^c   Penninks, André H ^a  

^a TNO   (Netherlands)

^b ProtAffin Biotechnologie AG   (Austria)

^c TNO Quality of Life ^*  (Denmark)

Author keywords

Anakinra; Anti drug antibodies; Immunogenicity; Minipigs; Pharmacokinetics

Indexed keywords

INTERLEUKIN 1ALPHA; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOPSY; BIOASSAY; BIOLOGICAL ACTIVITY; BODY WEIGHT; CLINICAL FEATURE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GOTTINGEN MINIPIG; HAPLORHINI; HISTOPATHOLOGY; IMMUNOGENICITY; IMMUNOLOGICAL TECHNIQUE; MALE; MINIPIG; NONHUMAN; ORGAN WEIGHT; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; WEIGHT;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; HUMANS; IMMUNOLOGIC TESTS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SWINE; SWINE, MINIATURE;

EID: 84874340173     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2012.735274     Document Type: Article

References (23)

1. Bode, G., Clausing, P., Gervais, F., Loegsted, J., Luft, J., Nogues, V., and Sims, J. 2010. The utility of the minipig as an animal model in regulatory toxicology. J. Pharmacol. Toxicol. Meth. 62: 196-220.
2. Brinks, V., Jiskoot, W., and Schellekens, H. 2011. Immunogenicity of therapeutic proteins: The use of animal models. Pharm. Res. 28: 2379-2385.
3. Bugelski, P. J., and Treacy, G. 2004. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6: 10-16.
4. Buttel, I. C., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P., Lubiniecki, A., Krause, R., Mire-Sluis, A., Platts-Mills, T., Ragheb, J. A., Reipert, B. M., Schellekens, H., Seitz, R., Stas, P., Subramanyam, M., Thorpe, R., Trouvin, J. H., Weise, M., Windisch, J., and Schneider, C. K. 2011. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39: 100-109.
5. Chirino, A. J., Ary, M. L., and Marshall, S. A. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 9: 82-90.
6. EMEA. 2006. Kineret: EPAR-Scientific Discussion.
7. FDA. 2000. Center for drug evaluation and research and center for biologics evaluation and research. Application number 103950/0.
8. FDA. 2001. Center for drug evaluation and research and center for biologics evaluation and research. Application number 103950/0; Approved labeling.
9. FDA (Food and Drug Administration) Arthritis Drugs Advisory Committee. 2001. Kineret TM (anakinra) FDA Arthritis Drugs Advisory Committee Briefing Package.
10. Forster, R., Ancian, P., Fredholm, M., Simianer, H., and Whitelaw, B. 2010a. The minipig as a platform for new technologies in toxicology. J. Pharmacol. Toxicol. Meth. 62: 227-235.
11. Forster, R., Bode, G., Ellegaard, L., and van der Laan, J. W. 2010b. The RETHINK project on minipigs in the toxicity testing of new medicines and chemicals: Conclusions and recommendations. J. Pharmacol. Toxicol. Meth. 62: 236-242.
12. Forster, R., Bode, G., Ellegaard, L., and van der Laan, J. W. 2010c. The RETHINK project-minipigs as models for the toxicity testing of new medicines and chemicals: An impact assessment. J. Pharmacol. Toxicol. Meth. 62: 158-159.
13. Getts, D. R., Getts, M. T., McCarthy, D. P., Chastain, E. M., and Miller, S. D. 2010. Have we over-estimated the benefit of human(ized) antibodies? MAbs 2: 682-694.
14. ICH. 2005. ICH S8. Immunotoxicity Studies for Human Pharmaceuticals.
15. Kromminga, A., and Schellekens, H. 2005. Antibodies against erythropoietin and other protein-based therapeutics: An overview. Ann. NY Acad. Sci. 1050: 257-265.
16. Penninks, A. H., and van Mierlo, G. J. 2012. Immunotoxicity studies in minipigs. In: The Minipig in Biomedical Research (McAnulty, P. A., Dayan, A. D., Ganderup, N. C., and Hastings, K. L., Eds.). New York: CRC Press/Taylor and Francis Group, pp. 397-414.
17. Ponce, R., Abad, L., Amaravadi, L., Gelzleichter, T., Gore, E., Green, J., Gupta, S., Herzyk, D., Hurst, C., Ivens, I. A., Kawabata, T., Maier, C., Mounho, B., Rup, B., Shankar, G., Smith, H., Thomas, P., and Wierda, D. 2009. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54: 164-182.
18. Regulatory Affairs Canada. 2008. Product Monograph PrKineret.
19. Schellekens, H. 2010. The immunogenicity of therapeutic proteins. Discov. Med. 9: 560-564.
20. Singh, S. K. 2011. Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 100: 354-387.
21. van der Laan, J. W., Brightwell, J., McAnulty, P., Ratky, J., and Stark, C. 2010. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals, and other products. J. Pharmacol. Toxicol. Meth. 62: 184-195.
22. Wierda, D., Smith, H. W., and Zwickl, C. M. 2001. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158: 71-74.
23. Zuurmond, A. M., Koudijs, A., van, E. B., Doornbos, R. P., van Manen-Vernooij, B. C., Bastiaans, J. H., Penninks, A. H., van Bilsen, J. H., Cnubben, N. H., and Degroot, J. 2011. Integration of efficacy, pharmacokinetic, and safety assessment of IL-1 receptor antagonist in a pre-clinical model of arthritis. Regul. Toxicol. Pharmacol. 59: 461-470.